---
document_datetime: 2025-11-23 08:01:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rhucin.html
document_name: rhucin.html
version: success
processing_time: 0.043111
conversion_datetime: 2025-12-28 08:58:37.14194
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rhucin

[RSS](/en/individual-human-medicine.xml/66935)

##### Refused

This medicine has been refused authorisation

recombinant human C1 inhibitor

Medicine

Human

Refused

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 13 December 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Rhucin 150 U/ml powder for solution for injection, intended for the treatment of acute attacks of angioedema in patients with congenital C1 inhibitor activity deficiency.

The company that applied for authorisation is Pharming Group N.V. It may request a re-examination of the opinion within 15 days of receipt of notification of this negative opinion.

Questions and answers on recommendation for the refusal of the marketing authorisation for  Rhucin

Reference Number: EMEA/567761/2007

English (EN) (35.01 KB - PDF)

**First published:** 13/12/2007

**Last updated:** 13/12/2007

[View](/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-rhucin_en.pdf-0)

## Product details

Name of medicine Rhucin Active substance recombinant human C1-inhibitor International non-proprietary name (INN) or common name recombinant human C1 inhibitor Therapeutic area (MeSH) Angioedema Anatomical therapeutic chemical (ATC) code B06C

### Pharmacotherapeutic group

Other hematological agents

## Application details

EMA product number EMEA/H/C/000769 Marketing authorisation applicant Pharming Group N.V. Opinion adopted 13/12/2007 Refusal of marketing authorisation 22/05/2008

## Assessment history

Rhucin : EPAR - Refusal public assessment report

English (EN) (768.59 KB - PDF)

**First published:** 27/06/2008

**Last updated:** 27/06/2008

[View](/en/documents/assessment-report/rhucin-epar-refusal-public-assessment-report_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 31/12/2009

## Share this page

[Back to top](#main-content)